Table 1.
Baseline maternal and patient characteristics of randomised patients
| Early pharmacological treatment (n= ) | Expectant management (n= ) | ||
|---|---|---|---|
| Maternal characteristics | Maternal age [years] | ||
| Maternal obstetrical disease | |||
| Pre-eclampsia | |||
| HELLP syndrome | |||
| Placental abruption | |||
| PPROM | |||
| Clinical chorioamnionitis | |||
| Maternal medication | |||
| NSAIDs | |||
| Magnesium sulphate | |||
| Tocolysis | |||
| Administration of ACS | |||
| ACS course completed | |||
| Type of delivery | |||
| Vaginal | |||
| Caesarean section | |||
| Multiple birth | |||
| Patient characteristics | Gestational age [weeks] | ||
| Birth weight [grams] | |||
| Outborn (yes) | |||
| Gender (male) | |||
| Apgar score at 5 minutes | |||
| Resuscitation after birth | |||
| Non-invasive respiratory support | |||
| Invasive respiratory support | |||
| Circulatory support | |||
| Respiratory distress syndrome | |||
| Surfactant administration | |||
| PDA diameter [mm] | |||
Data is presented as mean (± standard deviation) or median [interquartile ranges]. Categorical variables are presented as counts (percentage)
ACS antenatal corticosteroids, HELLP haemolysis, elevated liver enzymes and low platelets, PDA patent ductus arteriosus, PPROM preterm premature rupture of membranes, NSAIDs non-steroidal anti-inflammatory drugs, TTN transient tachypnea of the newborn